## Background: The development of malignant and benign tumors in patient with neurofibromatosis type 1 (nf1) was investigated in a long term follow-up study of 70 adult nf1 patients living in gΓΆteborg, sweden, on january 1, 1978. their mean age at that time was 44 years (range, 20-81 years). the 70
Chromosome 17 loss-of-heterozygosity studies in benign and malignant tumors in neurofibromatosis type 1
β Scribed by Sonja A. Rasmussen; Jennifer Overman; Susanne A.M. Thomson; Steven D. Colman; Corinne R. Abernathy; Rachael E. Trimpert; Rebecca Moose; Gurinder Virdi; Kyle Roux; Mislen Bauer; Amyn M. Rojiani; Bernard L. Maria; David Muir; Margaret R. Wallace
- Publisher
- John Wiley and Sons
- Year
- 2000
- Tongue
- English
- Weight
- 158 KB
- Volume
- 28
- Category
- Article
- ISSN
- 1045-2257
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
The tumor suppressor gene BRCA1 on chromosome 17q21 has been characterized and shown to be mutated in patients with familial breast and ovarian cancer. Several studies examined the relatives of women with breast cancer and noted an association with ovarian and prostate cancer. This study investigate
We have previously shown that all CBA/J mice exposed to 4-nitroquinoline-1-oxide (4NQO) eventually develop oral cavity squamous cell carcinomas, and two-thirds of these tumors have Ha-ras-1 (Hras1) point mutations at codon 12. Half of the tumors with Hras1 mutations have loss of heterozygosity (LOH)